Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVGV-1 Vaccine in Women With HPV Induced Cervical HSIL
NCT02576561Phase 2Unknown
- Sponsor
- TheVax Genetics Vaccine Co., Ltd.
- Start
- Nov 2015
- Primary completion
- May 2018
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TVGV-1 in Squamous Intraepithelial Lesion (SIL) (9 cohorts), sponsored by TheVax Genetics Vaccine Co., Ltd. Primary endpoints: Absence of histologic HSIL (CIN2/3) at Day 270 and Assessment of cutaneous toxicities at Day 270. Status: unknown.
02
Drugs
TVGV-1
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT02576561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576561.